1312809-83-8

Basic information

• Product Name: 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one
• Synonyms: 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one
• CAS NO: 1312809-83-8
• Molecular Weight: 477.268
• Mol File: 1312809-83-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one(1312809-83-8)
• EPA Substance Registry System: 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one(1312809-83-8)

Safety Data

• Hazardous Substances Data: 1312809-83-8(Hazardous Substances Data)

Upstream product

• 214117-50-7 2,4-dihydro-4-(4-bromophenyl)-3H-1,2,4-triazol-3-one 
• 86386-77-8 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole methanesulfonate 
• 106-40-1 4-bromo-aniline 
• 86404-63-9 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazolyl)ethanone 
• 51336-94-8 2-chloro-1-(2,4-dichlorophenyl)ethanone 
• 372-18-9 1,3-Difluorobenzene 

Relevant articles and documents

Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one

Based on the structure of the active site of cytochrome P450 14α-demethylase (CYP51) and the conclusions of the structure-activity relationships of azole antifungals, a series of 1-(2-(2,4-difluoro-phenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one of fluconazole analogs was synthesized. All compounds were characterized by IR, HRMS, 1HNMR and 13C NMR spectroscopic analysis. Results of preliminary antifungal in vitro test using eight human pathogenic species showed that some compounds displayed comparable or even better antifungal activities than reference drug fluconazole and that compound 3i exhibited significant activity against Candida albicans being worthy of further optimization.